For a healthy 16‑year‑old male with no prior meningococcal vaccination, is a two‑dose meningococcal vaccine schedule recommended?

Yes, a two-dose meningococcal vaccine schedule is strongly recommended for a healthy 16-year-old male with no prior vaccination.

For this unvaccinated 16-year-old, you should administer both MenACWY and MenB vaccines using a two-dose schedule for each vaccine type. This approach provides comprehensive protection against the five main disease-causing serogroups (A, C, W, Y, and B) that cause invasive meningococcal disease in adolescents 1.

MenACWY Vaccination (Serogroups A, C, W, Y)

Administer one dose of MenACWY immediately at age 16. Since this patient missed the routine 11-12 year dose, he is now in the catch-up window. The ACIP 2020 guidelines specify that although routine vaccination is recommended for adolescents aged 11-18 years, MenACWY may be administered to persons aged 19-21 years who have not received a dose after their 16th birthday 1.

• No booster is needed if the first dose is given at age 16 or later, as the preferred timing for the most recent dose is on or after the 16th birthday 1
• Any of the three MenACWY products (MenACWY-D, MenACWY-CRM, or MenACWY-TT) are interchangeable and acceptable 1

MenB Vaccination (Serogroup B)

Administer a two-dose MenB series based on shared clinical decision-making, with the preferred age being 16-18 years 1, 2. For healthy adolescents not at increased risk:

• MenB-FHbp (Trumenba): 2 doses at 0 and 6 months 2
• MenB-4C (Bexsero): 2 doses at least 1 month apart 1

Important: The two MenB vaccines are NOT interchangeable—you must use the same product for both doses 2.

Clinical Rationale

The two-dose approach is critical because:

1. Waning immunity: MenACWY vaccine effectiveness decreases from 79% at <1 year to 61% at 3-8 years post-vaccination 3. However, since this patient is receiving his first dose at age 16, he benefits from optimal timing without needing a booster.

2. Serogroup B burden: Serogroup B accounts for a significant proportion of meningococcal disease in adolescents and young adults, making MenB vaccination particularly relevant for this age group 4.

3. College risk: If this patient will be attending college and living in residence halls, vaccination is especially important as college freshmen in dormitories face increased risk 1.

Shared Clinical Decision-Making for MenB

While MenACWY is a routine recommendation (Category A), MenB vaccination is based on shared clinical decision-making (Category B) 2. Discuss with the patient:

• The serious nature of meningococcal disease with high mortality and permanent sequelae
• The relatively low but real incidence (average 34 serogroup B cases annually among 16-23 year-olds during 2015-2018) 1
• Increased risk for college students, especially freshmen in dormitories
• Protection against most serogroup B strains
• Relatively short duration of protection (antibody waning within 1-2 years) 1
• No evidence of herd protection from MenB vaccines 1

Administration Details

• Both vaccines can be given simultaneously at different anatomic sites 2
• Minimum interval between any two doses of MenB vaccine is 4 weeks 2
• Most common adverse reactions: injection site pain (≥85%), fatigue (≥40%), headache (≥35%), myalgia (≥30%), chills (≥15%) 2

Common Pitfall to Avoid

Do not delay MenACWY vaccination thinking a booster will be needed—when the first dose is given at age 16 or later, no booster is required unless more than 5 years elapse before college entry 1. This patient is already at the optimal age for a single MenACWY dose that will provide protection through young adulthood.